Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca Apr 02, 2015 MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US Mar 31, 2015 AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US Mar 19, 2015 Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control in Patients with Advanced Breast Cancer in Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08) Mar 17, 2015 Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain Feb 25, 2015 Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results Feb 24, 2015 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets Feb 17, 2015 Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A Feb 11, 2015 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 06, 2015 Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer Dec 11, 2014 Pagination First page « first Previous page ‹ previous … Page 22 Page 23 Page 24 Page 25 Current page 26 Page 27 Page 28 Page 29 Page 30 … Next page next › Last page last »